CLARITYN RAPIDE ALLERGY

Main information

  • Trade name:
  • CLARITYN RAPIDE ALLERGY
  • Dosage:
  • 10 Milligram
  • Pharmaceutical form:
  • Oral Lyophilisate
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • CLARITYN RAPIDE ALLERGY
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PA1286/032/003
  • Authorization date:
  • 26-11-2010
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

ClaritynRapideAllergy10mgTablets.

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachorallyophilisatecontains10mgloratadine.

Forafulllistofexcipients,seesection6.1.

3PHARMACEUTICALFORM

Orallyophilisate

White,round,tablet-shapedunitdebossedwith'C10'.

4CLINICALPARTICULARS

4.1TherapeuticIndications

ClaritynRapideAllergyTabletsareindicatedforthesymptomatictreatmentofallergicrhinitisandchronicidiopathic

urticaria.

4.2Posologyandmethodofadministration

Adultsandchildren12yearsofageandover:

10mgoncedaily(oneorallyophilisateoncedaily).

Theorallyophilisatemaybetakenwithoutregardtomealtime.

Children2to12yearsofagearedosedbyweight:

Bodyweightmorethan30kg:10mgoncedaily(oneorallyophilisateoncedaily).

The10mgstrengthorallyophilisateisnotappropriateforchildrenwithabodyweightlessthan30kg.

EfficacyandsafetyofClaritynRapideAllergyTabletsinchildrenunder2yearsofagehasnotbeenestablished.

Patientswithsevereliverimpairmentshouldbeadministeredalowerinitialdosebecausetheymayhavereduced

clearanceofloratadine.Aninitialdoseof10mgeveryotherdayisrecommendedforadultsandchildrenweighing

morethan30kg.

Nodosageadjustmentsarerequiredintheelderlyorinpatientswithrenalinsufficiency.

4.3Contraindications

ClaritynRapideAllergyTabletsarecontraindicatedinpatientswhoarehypersensitivetotheactivesubstanceortoany

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 19/04/2011 CRN 2080079 page number: 1

4.4Specialwarningsandprecautionsforuse

ClaritynRapideAllergyTabletsshouldbeadministeredwithcautioninpatientswithsevereliverimpairment(see

section4.2).

TheadministrationofClaritynRapideAllergyTabletsshouldbediscontinuedatleast48hoursbeforeskintestssince

antihistaminesmaypreventorreduceotherwisepositivereactionstodermalreactivityindex.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

Whenadministeredconcurrentlywithalcohol,ClaritynRapideAllergyTabletshavenopotentiatingeffectsas

measuredbypsychomotorperformancestudies.

PotentialinteractionmayoccurwithallknowninhibitorsofCYP3A4orCYP2D6resultinginelevatedlevelsof

loratadine(seeSection5.2),whichmaycauseanincreaseinadverseevents.

4.6Fertility,pregnancyandlactation

Loratadinewasnotteratogenicinanimalstudies.Thesafeuseofloratadineduringpregnancyhasnotbeen

established.TheuseofClaritynRapideAllergyTabletsduringpregnancyisthereforenotrecommended.

Loratadineisexcretedinbreastmilk,thereforetheuseofloratadineisnotrecommendedinbreast-feedingwomen.

4.7Effectsonabilitytodriveandusemachines

Inclinicaltrialsthatassesseddrivingability,noimpairmentoccurredinpatientsreceivingloratadine.However,

patientsshouldbeinformedthatveryrarelysomepeopleexperiencedrowsiness,whichmayaffecttheirabilityto

driveorusemachines.

4.8Undesirableeffects

Inclinicaltrialsinapaediatricpopulationchildrenaged2through12years,commonadversereactionsreportedin

excessofplacebowereheadache(2.7%),nervousness(2.3%)andfatigue(1%).

InclinicaltrialsinvolvingadultsandadolescentsinarangeofindicationsincludingARandCIU,atthe

recommendeddoseof10mgdaily,adversereactionswithloratadinewerereportedin2%ofpatientsinexcessof

thosetreatedwithplacebo.Themostfrequentadversereactionsreportedinexcessofplaceboweresomnolence

(1.2%),headache(0.6%),increasedappetite(0.5%)andinsomnia(0.1%).Otheradversereactionsreportedvery

rarelyduringthepost-marketingperiodarelistedinthefollowingtable.

Immunedisorders Anaphylaxis

Nervoussystemdisorders Dizziness

Cardiacdisorders Tachycardia,palpitation

Gastrointestinaldisorders Nausea,drymouth,gastritis

Hepato-biliarydisorders Abnormalhepaticfunction

Skinandsubcutaneoustissuedisorders Rash,alopecia

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 19/04/2011 CRN 2080079 page number: 2

4.9Overdose

Overdosagewithloratadineincreasedtheoccurrenceofanticholinergicsymptoms.Somnolence,tachycardiaand

headachehavebeenreportedwithoverdoses.

Intheeventofoverdosage,generalsymptomaticandsupportivemeasuresaretobeinstitutedandmaintainedforas

longasnecessary.

Administrationofactivatedcharcoalasaslurrywithwatermaybeattempted.Gastriclavageshouldbe

considered.Loratadineisnotremovedbyhaemodialysisanditisnotknownifloratadineisremovedbyperitoneal

dialysis.Medicalmonitoringofthepatientistobecontinuedafteremergencytreatment.

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

Pharmacotherapeuticgroup:antihistamines–H

antagonist,ATCcode:R06AX13

Loratadine,theactiveingredientinClaritynRapideAllergyTablets,isatricyclicantihistaminewithselective,

peripheralH

-receptoractivity.

Loratadinehasnoclinicallysignificantsedativeoranticholinergicpropertiesinthemajorityofthepopulationand

whenusedattherecommendeddosage.

Duringlong-termtreatmenttherewerenoclinicallysignificantchangesinvitalsigns,laboratorytestvalues,

physicalexaminationsorelectrocardiograms.

LoratadinehasnosignificantH

-receptoractivity,doesnotinhibitnorepinephrineuptakeandhaspracticallyno

influenceoncardiovascularfunctionoronintrinsiccardiacpacemakeractivity.

5.2Pharmacokineticproperties

Afteroraladministration,loratadineisrapidlyandwellabsorbed,andundergoesextensivefirstpassmetabolism,

mainlybyCYP3A4andCYP2D6.Themajormetabolite-desloratadine(DL)-ispharmacologicallyactiveand

responsibleforalargepartoftheclinicaleffect.LoratadineandDLachievemaximumplasmaconcentrations

)between1-1.5hoursand1.5-3.7hoursafteradministration,repectively.

Increaseinplasmaconcentrationsofloratadinehasbeenreportedafterconcomitantusewithketoconazole,

erythromycinandcimetidineincontrolledtrials,butwithoutclinicallysignificantchanges(including

electrodiographic).

Loratadineishighlybound(97%to99%)anditsactivemetabolitemoderatelybound(73%to76%)toplasma

proteins.

Inhealthysubjects,plasmadistributionhalf-livesofloratadineanditsactivemetaboliteareapproximately1and2

hours,respectively.Themeaneliminationhalf-livesinhealthyadultssubjectswere8.4hours(range=3to20

hours)forloratadineand28hours(range=8.8to92hours)forthemajoractivemetabolite.

Approximately40%ofthedoseisexcretedinurineand42%inthefaecesovera10dayperiodandmainlyinthe

formofconjugatedmetabolites.Approximately27%ofthedoseiseliminatedintheurineduringthefirst24

hours.Lessthan1%oftheactivesubstanceisexcretedunchangedinactiveform,asloratadineorDL.

Thebioavailabilityparametersofloratadineandoftheactivemetabolitearedoseproportional.

Thepharmacokineticprofileofloratadineanditsmetabolitesiscomparableinhealthyadultvolunteersandinhealthy

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 19/04/2011 CRN 2080079 page number: 3

Concomitantingestionoffoodcandelayslightlytheabsorptionofloratadinebutwithoutinfluencingtheclinical

effect.

Inpatientswithchronicrenalimpairment,boththeAUCandpeakplasmalevels(C

)increasedforloratadine

anditsmetaboliteascomparedtotheAUCsandpeakplasmalevels(C

)ofpatientswithnormalrenalfunction.

Themeaneliminationhalf-livesofloratadineanditsmetabolitewerenotsignificantlydifferentfromthatobserved

innormalsubjects.Haemodialysisdoesnothaveaneffectonthepharmacokineticsofloratadineoritsactive

metaboliteinsubjectswithchronicrenalimpairment.

Inpatientswithchronicalcoholicliverdisease,theAUCandpeakplasmalevels(C

)ofloratadineweredouble

whilethepharmacokineticprofileoftheactivemetabolitewasnotsignificantlychangedfromthatinpatientswith

normalliverfunction.Theeliminationhalf-livesforloratadineanditsmetabolitewere24hoursand37hours,

respectively,andincreasedwithincreasingseverityofliverdisease.

Loratadineanditsactivemetaboliteareexcretedinthebreastmilkoflactatingwomen.

5.3Preclinicalsafetydata

Preclinicaldatarevealnospecialhazardbasedonconventionalstudiesofsafety,pharmacology,repeateddose

toxicity,genotoxicityandcarcinogenicpotential.

Inreproductivetoxicitystudies,noteratogeniceffectswereobserved.However,prolongedparturitionandreduced

viabilityofoffspringwereobservedinratsatplasmalevels(AUC)10timeshigherthanthoseachievedwith

clinicaldoses.

Noevidenceofmucousmembraneirritationwasobservedafterdailyadministrationofupto12tablets(120mg)of

orallyophilisatesintothehamstercheekpouchforfivedays.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Gelatin

Mannitol(E421)

Citricacidanhydrous

Mintflavour

6.2Incompatibilities

Notapplicable.

6.3ShelfLife

2years.

6.4Specialprecautionsforstorage

Storeintheoriginalpackageinordertoprotectfrommoisture.

Thismedicinalproductdoesnotrequireanyspecialtemperaturestorageconditions.

6.5Natureandcontentsofcontainer

Unitdoseblistersconsistingofanopaquealuminumfoil-basedlaminateblisterfilm(polyvinylchloride(PVC)product

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 19/04/2011 CRN 2080079 page number: 4

Packsizesof7,8,10,20or30unitsoforallyophilisate.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsfordisposal

Nospecialrequirements.

7MARKETINGAUTHORISATIONHOLDER

MerckSharp&DohmeIreland(HumanHealth)Limited

PelhamHouse

SouthCountyBusinessPark

Leopardstown

Dublin18

Ireland

8MARKETINGAUTHORISATIONNUMBER

PA1286/32/3

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation:26 th

November1999

Dateoflastrenewal:8 th

November2007

10DATEOFREVISIONOFTHETEXT

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 19/04/2011 CRN 2080079 page number: 5